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Studies on animal models showed that the metabolic activity bones 
may promote formation and progression of bone metastases.  
It was therefore suggested that drugs inhibiting bone metabolism may 
locally protect bone in metastatic disease and inhibit growth of tumour . 
 
Aims 
The aim of this study is to assess the role of RANK-RANKL-OPG 
pathway either as predictive and diagnostic marker or as therapeutic 
follow-up of metastatic bone disease. 
 
Materials and methods 
A group of 100 patients affected by breast or prostate cancer with 
bone metastases (43 females and 57 male) was recruited a: 43 
females breast cancer patients were compared with 45 healthy 
women; 57 male prostate cancer patients were compared with 55 
healthy subjects.  
In order to evaluate calcium and phosphorus metabolism, bone 
metabolic markers, osteoprotegerin (OPG) and soluble receptor 
activator of nuclear factor-Kb ligand (sRANKL), all of the enrolled 
underwent a medical examination, bone densitometry and blood 
sampling.  
All patients with metastatic disease were treated with zoledronic acid 
(ZA) 4 mg i.v. every 4 weeks and revalued after 18 months (T1). 
 
Results 
Comparing patients with bone metastases from breast cancer to 
controls, RANKL/OPG ratio resulted increased in patients 
(23,68±13,69 vs 16,18±2,75 p<0,05), as well as serum levels in 
patients with prostate cancer OPG (4.0 ± 0.46 vs 4,2 ± 0.65 pmol/L; p 
< 0,05), while sRANKL/OPG was reduced (12,94 ± 3.65 vs 18.8 ± 
2.75%; p < 0,05).  
Densitometric follow-up of patients with breast cancer showed a 
significant increase of the T-score at lumbar site (Ts:-1,59±1,16DS vs 
0,89 ± 0,35 DS; p=0.04). 
Furthermore was not showed any significant variations of bone density 
in both lumbar (Ts: -1,4 ±0,3 vs -1,33±0,8 DS) and femoral site (Ts: -
0,9±0,75 vs -0,89±1,45 DS). 
 
Conclusions 
Results show that metastasis either from prostate or breast cancer is 
finely tuned by RANK-RANKL -OPG pathway and that ZA can play 





The process of metastasization takes place thanks to the release of 
growth factors which support metastatic lesions in growing within 
bones. 
Metastatic lesions persisting in several organs and tissues of patients 
affected by cancer, even after removal of primary tumour, do 
represent the pathophysiological base for the disease’s resurgence. 
The survival of such cells and the development of metastases depend 
on tissue microenvironment and on neoplastic cells ability to adapt 
their selves to that microenvironment (1-3). 
Particularly the bone tissue offers a favourable microenvironment both 
to survival and growth of cells from metastatic breast cancer, so 
causing significant morbidity and, consequentially, deteriorating life 
quality for patients (4-6). 
Studies on animal models have shown that bone metabolic activity 
may promote bone metastases formation and progression (7-9). 
Supporting these, clinical studies have shown a significant association 
between bone turn-over, tested by biochemical marker, and 
progression of metastatic bone disease (10,11). It has been therefore 
suggested that drugs inhibiting bone metabolism may locally protect 
bone in metastatic disease and inhibit growth of tumour . 
In fact, further studies on animal models with metastases from breast 
cancer have shown that reducing bone turn-over, before the 
colonisation by tumour cells takes place, can appreciably reduce 
metastatic lesions in number and in their progression (12-14).  
Nonetheless it has also been observed that, on animals with pre-
existing injury, the antiresorptive treatment by bisphosphonates does 
not affect the metastatic growth potential of cancer cells in the bone 
micro-environment, even if it does have an antiosteolytic effect (12,13). 
In order to explain such a phenomenon, it has to be considered that 
growth of tumour  is related to the degree of bone resorption 
suppression and thus to the dose of administered bisphosphonates; it 
has also to be considered that initial phase of growth of tumour  strictly 
depends on the interaction with the bone microenvironment, still being 
able to become independent afterwards and develop autonomously 
(13,15). 
In fact prostate and breast cancer frequently metastasize at bone level, 
where neoplastic cells induce formation of osteoclasts which leads to 
resorption of the bone itself. 
In 84% of patients, prostate cancer, the most frequent in males, 
causes bone metastases which determine alterations of both bone 
formation and resorption (16-19). 
It has also been shown that prostate cancer cells produce and secrete 
OPG (17) and produce the sRANKL that promote osteoclastogenesis. 
Further observations have revealed that particularly OPG may inhibit 
osteoclastogenesis by linking sRANKL, so preventing bone metastasis 
from developing (18, 20). 
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In vivo studies have highlighted that over-expression of OPG inhibits 
growth of tumour at bone level (21), and indirectly protects cancer 
cells from TRAIL mediated apoptosis (TNF-Related Apoptosis-
Inducing Ligand), thus helping their survival (17). 
Several studies, though conducted on small samples in order to reach 
definitive conclusions (17, 22), have found that serum levels of OPG 
were higher in patients with bone metastases from prostate cancer 
than in patients suffering just from prostate tumours (23).  
No correlation has been showed with regard to PSA levels; while in 
some case it has also been shown that the over-expression of OPG 
and increased OPG/RANKL ratio correlate with markers of disease, 
such as Gleason score, TNM, and PSA levels. 
All of the data so far reported suggest the opportunity of further 
studies in order to confirm the role of OPG as prognostic marker for 
prostate cancer. 
Breast cancer metastasis frequently cause osteolytic activity which is 
not directly mediated by cancer cells, but by osteoclasts (24, 25, 26). 
It has been shown that breast cancer cells do not express mRNA for 
RANKL, but, through interaction with bone marrow stromal cells and 
synthesis of PTHrP (parathyroid hormone-related protein), they can 
induce synthesis of RANKL as well as inhibit synthesis of OPG, so 
promoting the formation of osteoclasts and the growth of metastatic 
lesions (26, 27). 
In metastatic breast cancer lesions PTHrP is the main mediator of 
osteoclastic activation (28). 
After incretion of PTHrP, RANKL, which is produced by osteoblasts 
and stromal cells, links to RANK on osteoblastic precursors and 
induces the differentiation. 
The bioavailability of RANKL is controlled by OPG and OPG/RANKL 
ratio regulates the osteoclastogenesis process (29,30). 
It has also been found that, in metastatic lesions from breast cancer, 
OPG promote cancer cells survival by inhibiting activity of TRAIL 
(TNF-related Apoptosis Inducing Ligand) (26, 31, 32). 
 
Aims 
The aim of this study is to assess the role of RANK-RANKL-OPG 
pathway either as predictive and diagnostic marker or as therapeutic 
follow-up of metastatic bone disease. 
 
Materials and methods 
We have included in the study 100 patients suffering from bone 
metastasis from breast or prostate cancer, on average aged 57.6 ± 
10.4:  
Group of patients was compound of 43 women suffering from breast 
cancer and 57 male subjects affected by prostate cancer. All of them 
were compared with controls, which was on his turn compound of 45 
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healthy women and 55 healthy subjects not suffering either from any 
neoplastic pathology nor bone metabolic alterations. 
All of the enrolled subjects (T0) underwent medical examination, 
lumbar and femoral bone densitometry and collection of blood sample 
for evaluation of serum bone metabolic markers: bone alkaline 
phosphatase (BALP), c-telopepide of type 1 collagen (CTX) 
Osteocalcin (OC) for osteoprotegerina (OPG) and soluble receptor 
activator of nuclear factor-Kb ligand (sRANKL). 
All the serum assays have been processed by ELISA after storage at -
20°c. 
All of the patients affected by metastatic neoplastic pathology were 
treated, every 4 weeks, with zoledronic acid 4 mg for intravenous 
infusion lasting 15 minutes, and revalued after 18 months (T1). 
They underwent new medical examination, lumbar e femoral 
densitometry, and blood sampling for the determination of parameters 
already valued at T0. 
The statistical analysis has been implemented by multifactor analysis 
of variance (ANCOVA), taking body mass index (BMI), age and sex as 
covariates; and it was performed by using Statgraphic Plus 5.0 































Table 1 summarizes characteristics of population included in the study: 
i.e. patients with bone metastasis, respectively from breast and 
















Age 56,5±8,2 58,5 ± 5,21 58,7±12,6 60,3±8.7 
Weight (Kg) 64,4±9,8 74,7 ± 21,96 71±13,61 80±10,75 
Height (m) 1,58±0,073 1,55 ± 0,06 1,64±1.06 1,72±1,35 
BMI 25,7±4,40 30,89 ± 9,5 26,9± 5.5 27,5±6.2 
T-S lumbar 
(DS) -1,59±1,16 -1,03 ± 0,90 -1.4±0.3 -0.9±0.9 
Z-S lumbar 
(DS) -0,368±1,41 0,075 ± 0,87 -0.2±0.5 0.2±1.3 
T-S Femoral 
(DS) -0,452±0,94 -0,825 ± 0,87 -0.9±0.75 -0.4±1,03 
Z-S Femoral 
(DS) 0,452±1,10 0,068 ± 0,82 0.1±0.92 0.51±0.85 
sRANKL 
(pmol/L) 2,25±0,5 0,89±0,6 1,32±0,3 0,77±0,4 
OPG (pmol/L) 9,5±0,35 5,5±0,5 10,2±0,46 4,2±0,65 
sRANKL/OPG 
(x102) 23,68±13,69 16,18±2,75 12,94±3,65 18,8±2,75 
CTX (ng/ml) 0,65±0,1 0,63±0,25 0,73±0,28 0,55±0,25 
OC (ng/ml) 12,95±2,87 21,65±5,4 16,5±7,4 18,7±5,4 
BALP (IU/L) 49,88±14,27 22,7±10,62 48,6±31,5 25,4±10,62 
 
Analysis of variance, performed on densitometric data, shows lumbar 
density values, expressed by T-score, which appear reduced in breast 





The same trend has emerged from the analysis of variance of the 
lumbar Z-score variable (Fig 2) 
 
While analysis of variance performed on densitometric data, obtained 







Breast  Ca  Controls 
Means and 95,0 Percent LSD Intervals 
Lumbar 
T-score  
Fig. 1 Analysis of variance for the lumbar T-Score variable in the two 
study groups  
Breast Ca Controls 
Means and 95,0 Percent LSD Intervals 












The dosage of bone metabolism markers has showed that bone 
alkaline phosphatase serum concentration is significantly higher (p < 
0.001) in patients with bone metastases from breast cancer then in the 
healthy controls. While an opposite trend has been highlighted with 
Breast Ca Controls 
Means and 95,0 Percent LSD Intervals 
Femoral 
T-score 
Fig. 3 Analysis of variance for the Femoral T-Score 









Breast Ca Controls 
Means and 95,0 Percent LSD Intervals 
Femoral 
Z-score 
Fig. 4 Analysis of variance for the Femoral Z-Score 










regard to Osteocalcin, even if difference shown does not reach 






The measure of RANK-RANKL-OPG pathway factors has highlighted 
a sRANKL/OPG ratio significantly increased in patients with bone 








Fig. 5: OC and BALP serum levels of in patients with 
metastases from breast CA and in healthy subjects. 
Fig. 6 s-RANKL and OPG and s-RANKL/OPG serum levels in 
patients with metastases from breast CA and in healthy 
subjects 
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Densitometric follow-up after 18 months treatment with zoledronic acid 
i.v. has showed a significant increase of the densitometric parameters, 
particularly of the lumbar T-score (p = 0.04) (Fig.7 and 8), whereas it 










Fig 7 analysis of variance for the lumbar T-score 
before (T0) and after (T1) treatment with zoledronic 
acid 4 mg/4 weeks iv in patients suffering from 
breast cancer metastasis 
 
Fig 8 analysis of variance for lumbar Z-score before 














Fig 9 analysis of variance for the femoral T-score 
before (T0) and after (T1) treatment with zoledronic 
acid 4 mg/4 weeks i.v. in patients suffering from 






Fig 10 analysis of variance for the Femoral Z-score 
before (T0) and after (T1) treatment with zoledronic 
acid 4 mg/4 weeks i.v. in patients suffering from 
Breast cancer metastasis 
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The treatment resulted in clear reduction of serum CTX and BALP, but 




Fig.11 Analysis of variance of BALP variable before 
(T0) and after (T1) treatment with zoledronic acid 4 






Fig. 12 Analysis of variance of serum CTX, 
before (T0) and after (T1) treatment, in patients 




 T0 T1 
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The determination of serum sRANKL/OPG ratio has outlined a 




Fig. 13 Analysis of variance of sRANKL/OPG ratio in patients





With reference to the bone mass of patients with bone metastases 
from prostate cancer, the analysis of variance has showed lower bone 
mass in patients than in controls (Fig. 14,15). 
Lumbar  
T-score 
    Controls Prostate Ca 
Fig. 14 Analysis of variance of the lumbar T-score 
variable in patients suffering from bone metastasis 
from prostate cancer and healthy controls 
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A similar trend has benn highlighted at the femoral level, but neither it 
hasn’t reached statistical significance (fig. 16) 
 




T - score 




Fig. 16 Analysis of variance of the femoral T-
score between patients suffering from bone 
metastasis from prostate cancer and healthy 
controls 
Fig. 15 Analysis of variance of the lumbar Z-score 
variable in patients suffering from bone metastasis 
from prostate cancer and healthy controls 
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Statistical analysis of blood parameters under consideration has 
revealed that serum levels of OPG are increased in patients, 
compared to the control group (p < 0,05), whilst sRANKL/OPG ratio is 
reduced (p < 0,05) (Fig 17) 
 
 
Analysis of markers of bone metabolism has outlined increasing 
values for both bone resorption (CTX) and formation (BALP) (p<0,05) 
in patients suffering from bone metastasis from prostate cancer, if 





Fig. 17 Statistical analysis of serum OPG/sRANKL in patients suffering 
from bone metastases from prostate cancer compared to healthy 
controls 
Fig. 18 Serum CTX in patients suffering from bone metastases 






The following table (table 2) summarizes variations in parameters after 
the treatment with zoledronic acid IV for 18 months. 
 
 
Tabella 2 Ca prostate  (media +/- DS) 
Controllo a 18 mesi  
(media +/- DS) 
T-score lombare -1.4±0.3 -1,33±0.8 
Z-score lombare -0.2±0.5 0.19±1.2 
T-score femore -0.9±0.75 -0.89±1,45 
Z-score femore 0.1±0.92 0.09±0.73 
sRANKL (pmol/L) 1,32±0,3 1,56±0,2 
OPG (pmol/L) 10,2±0,46 17.72±0.85 
sRANKL/OPG (x102) 12,94±3,65 8,80±2.65 
CTX (ng/ml) 0,73±0,28 0.45±0,25 
OC (ng/ml) 16,5±7,4 11,42±5.4 
BALP (IU/L) 48,66±31,5 35,62±15.6 
 
Densitometric follow-up after 18 months from the beginning of 
treatment with zoledronic acid IV therapies has not showed significant 
changes in bone density at both lumbar (Fig 20 and 21) and femoral 
level (Fig 22 and 23). 
Fig 19 Serum OC and BALP concentrations in patients suffering 







Prostate Ca  
T1 
Prostate Ca  
T0 
Fig 20 Analysis of variance of the lumbar T-score 
variable before (T0) and after (T1) 18 months therapy in 
patients suffering from bone metastasis from prostate 
Fig 21 Analysis of variance of the lumbar Z-score 
variable before (T0) and after (T1) 18 months therapy in 





Prostate Ca  
T0 




The dosage of of bone metabolism markers, after 18 months of 
treatment, has showed a definite reduction of serum CTX (p < 0,05), 
Fig 22 Analysis of variance of the femoral T-score variable 
before (T0) and after (T1) 18 months therapy in patients 
suffering from bone metastasis from prostate cancer 
Prostate Ca  
T0 




Prostate Ca  
T0 
Prostate Ca  
T1 
Fig 23 Analysis of variance of the femoral z-score 
before (T0) and after (T1) therapy in patients suffering 




BALP and sRANKL/OPG, although the latter two have not reached 





Prostate Ca  
T0 
Prostate Ca  
T1 
Fig 24 Analysis of variance of serum BALP before (T0) 
and after (T1) 18 months therapy in patients suffering 
from bone metastasis from prostate cancer 
CTX 
ng/ml 
Fig 25 Analysis of variance of the serum CTX before 
(T0) and after (T1) 18 months therapy in patients 
suffering from bone metastasis from prostate cancer 
Prostate Ca  
T0 



























Fig 26 Analysis of variance of the sRANKL/OPG before 
(T0) and after (T1) 18 months therapy in patients 
suffering from bone metastasis from prostate cancer. 
Prostate Ca  
T0 






An emerging bulk of evidence emphasizes the crucial role of feedback 
interactions between tumor cells and bone marrow microenvironment 
leading to the establishment of a vicious circle which acts by 
upregulating the physiological mechanisms that normally favor bone 
resorption. Many researchers have reported that tumor cells mainly 
express RANKL when they adhere to the bone microenvironment 
(33,34). The nuclear factor kappa B, which is the one of the final 
transcriptional targets of the RANKL/RANK pathway, plays a key role 
in the induction of pro-inflammatory gene expression, leading to the 
synthesis of cytokines, adhesion molecules, chemokines, growth 
factors and enzymes (35)  
In the present study, our results suggest that imbalance of the 
physiological bone remodeling process is mediated by severe 
disruption of the sRANKL/OPG system towards either osteolysis or 
bone formation resulting in subsequent changes in the levels of the 
bone turnover markers.  
Our results also suggest that in patients with breast cancer there is a 
severe disruption in RANKL/OPG axis in favor of RANKL leading to 
increased osteoclast function.  
Subsequent rise in the levels of CTX reflect excessive bone resorption 
in this subset of patients, whereas increas in BALP and OPG levels 
possibly represents a compensatory effect of reactive bone formation, 
which, however, cannot counterbalance the increased bone 
destruction.  
On the contrary, OC was found to be down regulated, especially in the 
breast cancer subgroup, probably reflecting inefficient osteoblastic 
activity in these patients. Nevertheless, all the measured patient and 
control values of OC were within normal limits according to the 
manufacturer.  
Patients with prostate cancer metastatic to the skeleton seem to follow 
a rather different pattern of bone turnover with predominance of bone 
formation, reflected by increased levels of BALP, resulting in the well-
defined osteoblastic lesions. Prostate cancer cells seem to provoke 
profound elevation of OPG only, resulting in moderate suppression of 
the sRANKL/OPG ratio with subsequent increase in bone formation 
markers. It is thought today that the tumor microenvironment can 
release high amounts of OPG to counterbalance the high RANKL 
concentration produced by tumor cells. OPG acts in this case as a 
‘‘decoy’’ receptor of RANKL and must therefore be considered as a 
‘‘protector’’ of bone (36). Recently, promising results of a phase I 
study using recombinant OPG in patients with multiple myeloma or 
patients with breast cancer-related bone metastases were reported 
(37) and the future will show whether OPG has a therapeutic potential 
in this area. 
Several considerations have been raised regarding the results of bone 
markers’ measurements. It must be noted that absolute changes in 
marker values are often misleading if the interpretation does not take 
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into account the respective marker’s analytical and biological 
variability. It has recently been reported that serum levels of CTX and 
OC follow a circadian rhythm as a result of diurnal variation of 
cortisole in both breast cancer patients and healthy controls (38). This 
fact could possibly explain the failure of these two markers to correlate 
adequately with increased osteoclastic and osteoblastic activity, 
respectively, in the present study. Fohr et al. suggested that a change 
of 30% in a bone formation marker should be considered significant, 
whereas for most bone resorption markers, the least significant 
change should be at least 60% because of their higher coefficient 
variation (39). 
A consideration of this study is the low number of patients.  
The impact of previously received or concurrent chemotherapy (CT) 
and whether or not hormonal supplements or targeted hormonal 
therapies (estrogens, anti-estrogens, anti-androgens, aromatase 
inhibitors and LHRH analogs) were included in the treatment regimen 
is also an issue of major concern, due to the profound effects of 
hormonal intervention onto bone metabolic process (40). Marker 
levels might also be expected to change during the course of the 
disease, either in response to the effects of antineoplastic therapy-
which may obscure the original differences in marker levels between 
patients and controls- or due to disease progression or regression (41). 
In patients with breast cancer metastatic to bone, a rise in serum OC 
or BALP after CT has been associated with local recalcification and 
therefore considered as a sign of therapeutic success (42). Recent 
data indicate that high baseline levels of OC could be predictive of 
better progression-free survival in patients with hormone-refractory 
prostate cancer (43). Increased uNTX levels have been recently 
shown to correlate negatively with clinical outcome and with 2-fold 
increase in the risk for skeletal complications and disease progression 
(44). 
Recently, promising results of a phase I study using recombinant OPG 
in patients with multiple myeloma or patients with breast cancer-
related bone metastases were reported (37) and the future will show 
whether OPG has a therapeutic potential in this area. 
Our results suggest that antiresorptive therapy may affect bone 
metabolism through its action on OPG/RANKL/RANK pathway. 













Skeletal morbidity remains a major problem in cancer patients and 
many aspects of the pathophysiology of malignant bone disease have 
not yet been fully clarified. Although the central role of the 
sRANKL/OPG system in both physiological and pathological bone 
remodeling process has been elucidated, it remains unlikely that a 
single marker has sufficient diagnostic or prognostic value in 
malignant bone disease. 
Further larger-scale studies to assess the clinical utility of the 
combination of these markers with other laboratory tests (e.g. tumor 
markers) or imaging techniques are therefore required. Furthermore, 
important clinical questions regarding the use of these markers in 
monitoring bisphosphonate therapy or their prognostic value in 
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